-

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2025 financial results. Management will also discuss financial expectations for 2026 and provide an update on the company.

The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contacts

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Alkermes plc

NASDAQ:ALKS

Release Versions

Contacts

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

More News From Alkermes plc

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8, 2026 in Colorado Springs, Colo. The company will present data related to LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil) and LUMRYZ® (sodium oxybate) extended-release oral suspension, as well as alixorexton, the company’s novel, investigation...

Alkermes to Present at Upcoming Investor Conferences

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14...

Alkermes plc Reports Third Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provide an update on the company. The webcast may be accessed...
Back to Newsroom